Oral Glucose Tolerance Test Effects on Endothelial Inflammation Markers in Healthy Subjects and Diabetic Patients

Abstract

The aim of this study was to evaluate the effect of an oral glucose tolerance test (OGTT) on the level of endothelial dysfunction and vascular inflammation markers in healthy subjects (H) and diabetic overweight patients (D). We enrolled 256 healthy subjects and 274 type 2 diabetic patients. We evaluated blood glucose (BG), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), high-sensitivity C reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), and tumor necrosis factor-α (TNF-α) at baseline and after OGTT. We observed that BG, sICAM-1, IL-6, hs-CRP, sVCAM-1, sE-selectin, and TNF-α values were higher in D group than in H group. In a large sample of adult healthy subjects and type 2 diabetics we observed that both answer to an OGTT with a significant increase in biomarkers of systemic low-grade inflammation and endothelial dysfunction such as hsCRP, IL-6, TNF-α, sICAM-1, sVCAM-1, and sE-selectin. Type 2 diabetics experienced, however, a more significant increase in TNF-α, and sE-selectin.

Key words

type 2 diabetes mellitus - soluble adhesion molecules - vessels dysfunction - cardiovascular risk

References

• 1 Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: targets and interventions.  Diabetes Care. 2008;  31 ((Suppl 2)) S215-S221
• 2 Bartnik M, Norhammar A, Rydén L. Hyperglycaemia and cardiovascular disease.  J Intern Med. 2007;  262 145-156
• 3 Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.  Diabetes Care. 2008;  31 ((Suppl 2)) S155-S160
• 4 Asadollahi K, Beeching N, Gill G. Hyperglycaemia and mortality.  J R Soc Med. 2007;  100 503-507
• 5 Bell DS, O’Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?.  Endocr Pract. 2008;  14 112-124
• 6 Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose – a review of diagnosis, clinical implications and management.  Diab Vasc Dis Res. 2005;  2 9-15
• 7 American Diabetes Association. . Screening for diabetes (Position Statement).  Diabetes Care. 2001;  24 S21-S24
• 8 World Health Organization. . Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity. Geneva: WHO June 1997
• 9 European Diabetes Policy Group. . A desktop guide to type 2 diabetes mellitus.  Diab Med. 1999;  16 716-730
• 10 Song M, Kellum JA. Interleukin-6.  Crit Care Med. 2005;  33 S463-465
• 11 Zhang M, Tracey K. The Cytokine Handbook. 3rd ed. San Diego: Academic Press 1988
• 12 Rifai N, Tracy RP, Ridker PM. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay.  Clin Chem. 1999;  45 2136-2141
• 13 Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview.  Eur Cytokine Netw. 2004;  15 91-98
• 14 Peter K, Weirich U, Nordt TK, Ruef J, Bode C. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis.  Thromb Haemost. 1999;  82 38-43
• 15 Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease.  Clin Chim Acta. 2006;  368 33-47
• 16 American Diabetes Association. . Standards of Medical Care in Diabetes.  Diabetes Care. 2007;  30 S4-S41
• 17 Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York: McGraw-Hill 1971
• 18 Matthews JNS, Altman DG, Campbell MJ, Royton P. Analysis of serial measurements in medical research.  BMJ. 1990;  300 230-235
• 19 Tanabe N, Saito K, Yamada Y, Takasawa T, Seki N, Suzuki H. Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes.  Intern Med. 2009;  48 401-409
• 20 Ferri C, Desideri G, Baldoncini R, Bellini C, De Angelis C, Mazzocchi C, Santucci A. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities.  Diabetes. 1998;  47 660-667
• 21 Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. High serum concentrations of soluble E-selectin in patients with impaired glucose tolerance with hyperinsulinemia.  Atherosclerosis. 2000;  152 415-420
• 22 Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes.  Diabetologia. 2002;  45 210-216
• 23 Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro.  Diabetes. 1996;  45 954-959
• 24 Ruotsalainen E, Vauhkonen I, Salmenniemi U, Pihlajamäki J, Punnonen K, Kainulainen S, Jalkanen S, Salmi M, Laakso M. Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects.  Atherosclerosis. 2008;  197 271-277
• 25 Kowalska I, Straczkowski M, Szelachowska M, Kinalska I, Prokop J, Bachórzewska-Gajewska H, Stepien A. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism.  Metabolism. 2002;  51 733-736
• 26 Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes.  Ann N Y Acad Sci. 1995;  748 562-570
• 27 Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes.  J Clin Endocrinol Metab. 2000;  85 2970-2973
• 28 Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, Esposito K, Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.  Circulation. 2005;  111 2518-2524
• 29 Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, Chaudhuri A, Dandona P. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects.  Metabolism. 2006;  55 1177-1185
• 30 Dhindsa S, Tripathy D, Mohanty P, Ghanim H, Syed T, Aljada A, Dandona P. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells.  Metabolism. 2004;  53 330-334
• 31 Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment.  Diabetes. 2004;  53 701-710
• 32 Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress.  Circulation. 2002;  106 2067-2072
• 33 Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.  J Am Coll Cardiol. 2002;  39 1145-1150
• 34 Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb U. Inflammation in Metabolic Syndrome and Type 2 Diabetes. Impact of Dietary Glucose.  Ann N Y Acad Sci. 2006;  1084 30-48
• 35 Derosa G, D’Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.  Intern Med. 2007;  46 1837-1846
• 36 Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.  Clin Ther. 2004;  26 744-754
• 37 LeRoith D. Treatment of diabetes: a clinical update on insulin trials.  Clin Cornerstone. 2007;  8 2129
• 38 Derosa G, Fogari E, Cicero AF, D’Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.  Hypertens Res. 2007;  30 387394
• 39 Bogdanski P, Pupek-Musialik D, Dytfeld J, Jagodzinski PP, Jablecka A, Kujawa A, Musialik K. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus.  Int J Clin Pharmacol Ther. 2007;  45 563-567

Correspondence